Halozyme Therapeutics Inc [HALO] stock is trading at $76.07, up 0.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The HALO shares have gain 3.72% over the last week, with a monthly amount glided 20.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on August 06, 2025, when Morgan Stanley upgraded its rating to a Overweight but kept the price target unchanged to $75 for it. On May 14, 2025, downgrade downgraded it’s rating to Equal-Weight but maintained its price target of $62 on the stock. Leerink Partners downgraded its rating to a Underperform but stick to its price target of $47 on May 13, 2025. Wells Fargo downgraded its rating to a Equal Weight and raised its price target to $62 on October 07, 2024. JP Morgan downgraded its rating to Neutral for this stock on September 19, 2024, and upped its price target to $57. In a note dated June 07, 2024, Piper Sandler downgraded an Neutral rating on this stock and boosted its target price from $48 to $51.
Halozyme Therapeutics Inc [HALO] stock has fluctuated between $42.01 and $76.28 over the past year. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $76.07 at the most recent close of the market. An investor can expect a potential drop of -18.5% based on the average HALO price forecast.
Analyzing the HALO fundamentals
Halozyme Therapeutics Inc [NASDAQ:HALO] reported sales of 1.18B for the trailing twelve months, which represents a growth of 40.79%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.58%, Pretax Profit Margin comes in at 0.59%, and Net Profit Margin reading is 0.47%. To continue investigating profitability, this company’s Return on Assets is posted at 0.27, Equity is 1.37 and Total Capital is 0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of4.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 75.25 points at the first support level, and at 74.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 76.50, and for the 2nd resistance point, it is at 76.92.
Ratios To Look Out For
For context, Halozyme Therapeutics Inc’s Current Ratio is 8.36. On the other hand, the Quick Ratio is 7.01, and the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 7.55, the price to book ratio is 26.89 and price to earnings (TTM) ratio is 17.38.
Transactions by insiders
Recent insider trading involved Torley Helen, PRESIDENT AND CEO, that happened on Sep 03 ’25 when 20000.0 shares were sold. PRESIDENT AND CEO, Torley Helen completed a deal on Sep 04 ’25 to sell 20000.0 shares. Meanwhile, PRESIDENT AND CEO Torley Helen sold 20000.0 shares on Sep 02 ’25.
